Reports
Sale
Global Oral Proteins and Peptides Market Size, Share, Growth: By Drug Type: Plecanatide, Linaclotide, Octreotide, Calcitonin, Insulin; By Application: Gastric and Digestive Disorders, Bone Diseases, Diabetes, Hormonal Disorders; By End User: Hospitals, Ambulatory Surgical Centre, Clinics; Regional Analysis; Supplier Landscape; 2024-2032
Global Oral Proteins and Peptides Market Outlook
The global oral proteins and peptides market size was valued at USD 2.5 billion in 2023, driven by the growing biotechnological and pharmaceutical advancements across the globe. The market is expected to grow at a CAGR of 14.5% during the forecast period of 2024-2032, with the values likely to rise from USD 2.8 billion in 2024 to USD 8.3 billion by 2032.
Global Oral Proteins and Peptides Market Overview
Oral proteins and peptides involve the administration of large biomolecules orally, usually in the form of capsules, pills, or liquid formulations. Oral delivery is commonly preferred over the intravenous methods as it offers a patient friendly and painless option. The non-invasive nature of oral route of drug administration leads to improved quality of life, especially for those requiring long-term or chronic treatment. It may also facilitate fewer visits to the healthcare facilities and a minimized risk of infection. Such factors have led to increased oral proteins and peptides market demand in recent years.
Increasing Burden of Chronic Diseases to be the Key Growth Driver
Oral insulin is a key area of research owing to the rising prevalence of diabetes. Currently, approximately half a billion people are living with diabetes worldwide and the incidence is expected to rise to double and reach 1.3 billion in the next 30 years . Therefore, oral proteins and peptides can be considered as a convenient way to offer improved and effective solutions for the patients suffering from the disease. They are also being investigated to treat other conditions such as osteoporosis, cancer, inflammatory bowel disease, and autoimmune diseases and the growing prevalence of such diseases is anticipated to boost the oral peptides and proteins market growth in the forecast period.
Surge in Technical Advancements to Develop New Drugs
With increasing advancements in biotechnology as well as gene technology, designing oral peptides has also become comparatively easier. Researchers can now combat the constraints of oral peptide and protein delivery systems which include unfavourable physicochemical properties such as large molecular size, along with the tendency to undergo enzymatic degradation, aggregation, adsorption, and denaturation. Such technical innovations are expected to boost the oral proteins and peptides market size. In January 2023, the scholars at Uppsala University constructed a new machine for protein separation. The new method helps in capillary electrophoresis (which helps in molecular segregation based on different charges) in a cost-effective manner.
Expediated Drug Development to Address Multiple Diseases
In November 2023, Entera Bio Ltd., an oral peptide company, revealed development on five new oral peptides programs. There is development on the first Osteoporosis oral and osteoanabolic drug, called EB613. The company partnered with the American Society for Bone and Mineral Research (ASBMR) to submit the drug for FDA approval. The oral proteins and peptide market share is anticipated to grow with increased number of drugs under pipeline for multiple diseases. EB613 for intense sports and military stress injuries, EB612 for hypoparathyroidism, GLP-2 peptide tablets for short bowel syndrome, and GLP-1 peptides for obesity are some of the prominent examples of drugs under a pipeline.
Development of New Devices to Facilitate Oral Route of Administration
In September 2023, Biora Therapeutics, Inc., revealed their company’s latest invention, a BioJet™ platform for oral and systemic delivery of biotherapeutics. The platform uses an ingestible capsule, approximately like the size of a multivitamin and designed to transit through the digestive system and get activated in the small intestine. It can be used to deliver a wide of molecules including proteins, nucleic acids, and peptides in liquid formulations up to 400µL. It is an effective needle free route of delivering large molecules and is expected to replace injections for better management of chronic diseases.
Global Oral Proteins and Peptides Market Segmentation
Market Breakup by Drug Type
- Plecanatide
- Linaclotide
- Octreotide
- Calcitonin
- Insulin
Market Breakup by Application
- Gastric and Digestive Disorders
- Bone Diseases
- Diabetes
- Hormonal Disorders
Market Breakup by End User
- Hospitals
- Ambulatory Surgical Centre
- Clinics
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Oral Proteins and Peptides Market Regional Analysis
North America, led by the United States and Canada, is expected to lead the oral proteins and peptides market share in the forecast period. The market size can be accredited to a robust biotech along with research and development infrastructure. The existence of proactive regulatory authorities like the FDA also ensures the drug efficacy and contributes to the growth of the market.
With the presence of key academic institutions and pharmaceutical companies, Europe is another major market for oral proteins and peptides. The rising partnerships between the public and private entities is also garnering developments in the drug markets. The high prevalence of diseases such as diabetes and other bone related issues in the geriatric population also pushes innovation for improved patient alternatives.
Asia Pacific is expected to witness the oral proteins and peptides market growth attributed to rising investment in improving the research and development infrastructure. Moreover, the increasing influx of foreign capital is a major aspect of the market growth.
Global Oral Proteins and Peptides Market: Competitor Landscape
In September 2023, Entera Bio Ltd. partnered with OPKO Health, Inc., under a research agreement to expand their oral delivery technology across two extra peptides, namely GLP-2 for the treatment of short bowel syndrome, and Oxyntomodulin (OXM), a dual targeted GLP-1/glucagon agonist for treating obesity. Under the terms of the agreement, the companies will be responsible for specific phases of development leveraging their area of expertise.
The key features of the oral proteins and peptides market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Novo Nordisk A/S
- Synergy Pharmaceuticals Inc.
- Chiasma Inc.
- Tarsa Therapeutics Inc.
- Biocon Limited
- Generex Biotechnology Corp.
- AstraZeneca PLC
- Proxima Concepts Limited
- Oramed Pharmaceuticals Inc.
- Allergan Plc.
- Generex Biotechnology Corp.
- Hoffmann-La Roche
- Sanofi
- Bristol-Myers Squibb Company
- Hovione
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Type |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Oral Proteins and Peptides Market Overview
3.1 Global Oral Proteins and Peptides Market Historical Value (2017-2023)
3.2 Global Oral Proteins and Peptides Market Forecast Value (2024-2031)
4 Global Oral Proteins and Peptides Market Landscape
4.1 Global Oral Proteins and Peptides Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Oral Proteins and Peptides Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Products
5 Global Oral Proteins and Peptides Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis`
6 Global Oral Proteins and Peptides Market Segmentation
6.1 Global Oral Proteins and Peptides Market by Drug Type
6.1.1 Market Overview
6.1.2 Plecanatide
6.1.3 Linaclotide
6.1.4 Octreotide
6.1.5 Calcitonin
6.1.6 Insulin
6.2 Global Oral Proteins and Peptides Market by Application
6.2.1 Market Overview
6.2.2 Gastric and Digestive Disorders
6.2.3 Bone Diseases
6.2.4 Diabetes
6.2.5 Hormonal Disorders
6.3 Global Oral Proteins and Peptides Market by End User
6.3.1 Market Overview
6.3.2 Hospitals
6.3.3 Ambulatory Surgical Centre
6.3.4 Clinics
6.4 Global Oral Proteins and Peptides Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Oral Proteins and Peptides Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Oral Proteins and Peptides Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Oral Proteins and Peptides Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
1.1 ASEAN
9.5 Others
10 Latin America Oral Proteins and Peptides Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Oral Proteins and Peptides Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Novo Nordisk A/S
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisition
17.1.5 Certifications
17.2 Synergy Pharmaceuticals Inc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisition
17.2.5 Certifications
17.3 Chiasma Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisition
17.3.5 Certifications
17.4 Tarsa Therapeutics Inc.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisition
17.4.5 Certifications
17.5 Biocon Limited
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisition
17.5.5 Certifications
17.6 Generex Biotechnology Corp.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisition
17.6.5 Certifications
17.7 AstraZeneca PLC
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisition
17.7.5 Certifications
17.8 Proxima Concepts Limited
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisition
17.8.5 Certifications
17.9 Oramed Pharmaceuticals Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisition
17.9.5 Certifications
17.10 Allergan Plc.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisition
17.10.5 Certifications
17.11 Generex Biotechnology Corp.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisition
17.11.5 Certifications
17.12 Hoffmann-La Roche
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisition
17.12.5 Certifications
17.13 Sanofi
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisition
17.13.5 Certifications
17.14 Bristol-Myers Squibb Company
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisition
17.14.5 Certifications
17.15 Hovione
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisition
17.15.5 Certifications
18 Global Oral Proteins and Peptides Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 2.5 billion in 2023, driven by the rising biotechnological and pharmaceutical advancements across the globe.
The market is anticipated to grow at a CAGR of 14.5% during the forecast period of 2024-2032, likely to reach a market value of USD 8.3 billion by 2032.
The market demand has increased due to rising application of oral proteins and peptides in place of intravenous injections, owing to advantages like reduced chances of infection, high bioavailability of drugs and less painful administration. Increased drug development and research activities are other key drivers.
The major market trend constitutes increasing partnerships amongst companies to develop better and effective drugs. For instance, In September 2023, Entera Bio partnered with OPKO Health, Inc., to develop two peptides, namely GLP-2 for the treatment of short bowel syndrome, and oxyntomodulin, a dual targeted GLP-1/glucagon agonist for treating obesity.
Based on drug types, the market is divided into plecanatide, linaclotide, octreotide, calcitonin, and insulin.
Major end users include hospitals, clinics, and ambulatory surgical centres.
Common application areas include gastric and digestive disorders, bone diseases, diabetes, and hormonal disorders.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market.
Key players involved in the market are Novo Nordisk A/S, Synergy Pharmaceuticals Inc., Chiasma Inc., Tarsa Therapeutics Inc., Biocon Limited, Generex Biotechnology Corp., AstraZeneca PLC, Proxima Concepts Limited, Oramed Pharmaceuticals Inc., Allergan Plc., Generex Biotechnology Corp., Hoffmann-La Roche, Sanofi, Bristol-Myers Squibb Company, and Hovione.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER